-
The FDA has approved a non-halogenated nasal steroid for use in pediatric patients aged 6 to 12 years and adults. Ciclesonide is a prodrug that was previously approved for adults and adolescents but was not marketed. It's to be marketed by Nycomed US Inc. as Omnaris.
-
-
These three studies published back to back in the Journal of Infectious Diseases serve to better characterize HPV infection in heterosexual men.
-
Cognitive decline after surgery requiring cardio-pulmonary bypass (CPB) may be due to cellular debris picked up by the cardiotomy suction device.
-
-
In this issue: FDA warnings for existing drugs dominate pharmaceutical news this month.
-
Previously, the recommendation in the United States for post-exposure prophylaxis of hepatitis A virus (HAV) infection has consisted of the administration of a single dose of immune serum globulin (ISG).
-
-
Though recent conflicting studies and commentaries have thoroughly confused the issue, the take-home message for infection control professionals which passes muster with all but the most strident critics is that the elderly should be immunized against seasonal influenza. Period.
-
Regardless of the current controversy regarding the efficacy of seasonal influenza vaccination in the elderly, it seems a given that seniors will fare much worse should a pandemic strain arise that eludes an immune response in all ages. But under closer scrutiny, that logic does not hold.
